Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
暂无分享,去创建一个
[1] F. Roila,et al. RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature , 2020, Oncology and Therapy.
[2] Yi-long Wu,et al. Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study , 2020, Journal of Hematology & Oncology.
[3] M. Ladanyi,et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. , 2020, The Lancet. Oncology.
[4] N. Pennell,et al. Phase Ib Study of Crizotinib Plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation. , 2020, The oncologist.
[5] A. Akram,et al. The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy , 2020, Frontiers in Oncology.
[6] P. Korkolopoulou,et al. Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data , 2020, Virchows Archiv.
[7] P. Fournel,et al. Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma , 2020, Medicine.
[8] A. Drilon,et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.
[9] A. Drilon,et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.
[10] S. Digumarthy,et al. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50% , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] Q. Ou,et al. Distribution of NRG1 Gene Fusions in a Large Population of Chinese Patients with NSCLC. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] A. Shaw,et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. , 2019, The Lancet. Oncology.
[13] A. Drilon,et al. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers , 2019, Journal of Thoracic Oncology.
[14] E. Sokol,et al. NTRK1-3 genomic fusions in non-small cell lung cancer (NSCLC) determined by comprehensive genomic profiling , 2019, Annals of Oncology.
[15] A. Drilon,et al. NRG1 Fusion-Positive Lung Cancers: Clinicopathologic Profile and Treatment Outcomes from a Global Multicenter Registry , 2019, Lung cancer.
[16] Dong-Wan Kim,et al. The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer , 2019, Thoracic cancer.
[17] K. Nouri,et al. A kinome‐wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[18] Kengo Watanabe,et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models , 2019, Nature Communications.
[19] A. Drilon,et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] K. Boucher,et al. Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up , 2019, Targeted Oncology.
[21] Michael Thomas,et al. Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). , 2019, Journal of Clinical Oncology.
[22] A. Drilon,et al. Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). , 2019, Journal of Clinical Oncology.
[23] M. Ladanyi,et al. Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers , 2019, JCO precision oncology.
[24] Edward S. Kim,et al. Detection of NRG1 Gene Fusions in Solid Tumors , 2019, Clinical Cancer Research.
[25] S. C. Wang,et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] A. Shaw,et al. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] A. Tafreshi,et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] V. Miller,et al. Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[29] D. Aisner,et al. Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer , 2018, Cancer.
[30] A. Shaw,et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. , 2018, The Lancet. Oncology.
[31] Yi-long Wu,et al. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. , 2018, Lung cancer.
[32] A. Drilon,et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] C. Gridelli,et al. Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[34] J. Ahn,et al. Characteristics and Outcome of ROS1‐Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[35] Toyoaki Hida,et al. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[36] J. Shih,et al. Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer , 2018, Neoplasia.
[37] M. Socinski,et al. Abstract CT076: IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups , 2018, Clinical Trials.
[38] J. Szustakowski,et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. , 2018, Cancer discovery.
[39] K. Darwiche,et al. MET Expression in Advanced Non–Small‐Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy , 2018, Clinical lung cancer.
[40] E. Brambilla,et al. MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer , 2018, Clinical Cancer Research.
[41] Federico Cappuzzo,et al. Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.
[42] N. Pavlakis,et al. ENCORE: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs. crizotinib (CZ) in untreated advanced ALK+ NSCLC , 2018, Pneumologie.
[43] D. Chakrabarti,et al. Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101. , 2018 .
[44] S. Gettinger,et al. Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC). , 2018 .
[45] J. Lai,et al. MET gene fusions in non-small cell lung cancer (NSCLC) in the Chinese population: A multicenter study. , 2018 .
[46] D. Spigel,et al. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First‐Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370) , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[47] S. Sudarsanam,et al. Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer , 2018, Oncotarget.
[48] A. Iafrate,et al. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] M. Castellone,et al. RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2). , 2017, Endocrine-related cancer.
[50] H. Shim,et al. PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors , 2017, Oncotarget.
[51] R. Doebele,et al. Dramatic Response to Crizotinib in a Patient with Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion. , 2017, JCO precision oncology.
[52] G. Scagliotti,et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. , 2017, The Lancet. Oncology.
[53] D. Lipson,et al. RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients , 2017, Clinical lung cancer.
[54] Rafal Dziadziuszko,et al. Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[55] S. Kobayashi,et al. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3–PD‐L1 ≥50% Expression in Lung Adenocarcinoma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[56] R. Chiari,et al. Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence , 2017, Medical Oncology.
[57] P. Laurent-Puig,et al. Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy , 2017, Oncoimmunology.
[58] Serafino Pantano,et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study , 2017, The Lancet.
[59] V. Gebski,et al. Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[60] Lauren L. Ritterhouse,et al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. , 2016, Cancer discovery.
[61] Yiping Zhang,et al. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma , 2016, Journal of Translational Medicine.
[62] S. Digumarthy,et al. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.
[63] Philip J. Stephens,et al. Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. , 2016 .
[64] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[65] Dong-Wan Kim,et al. EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3 , 2016, Oncoimmunology.
[66] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[67] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[68] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[69] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[70] F. Garrido,et al. Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms , 2014, Oncogene.
[71] William Pao,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.
[72] P. Dessen,et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.
[73] J. C. Love,et al. In vivo discovery of immunotherapy targets in the tumour microenvironment , 2014, Nature.
[74] M. Wasik,et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) , 2008, Proceedings of the National Academy of Sciences.
[75] R. Hofstra,et al. MEN2A-RET-induced cellular transformation by activation of STAT3 , 2001, Oncogene.
[76] Keunchil Park,et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. , 2018, The Lancet. Oncology.
[77] M. Lawrence,et al. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. , 2018, Cancer discovery.